The newly merged NEOMED-LABS / Pacific Biomarkers, an immunology centric service provider specialized in assay development and clinical laboratory testing for vaccines and soluble large molecules, announced today the appointment of Tim McGrath to the role of Chief Operating Officer. In his role, he will contribute to the integration of business operations to ensure efficiency and bring the best market practices on board.
With over 30 years of general management and global operations experience, McGrath has worked extensively in laboratory and commercial settings, including Quintiles Transnational and Q2 Solutions, where he served as the Global Head for Bioanalytical, Immunoassay, and Absorption, Distribution, Metabolism and Excretion (ADME) laboratories. He was responsible for multiple sites in the U.S. and Europe and was the Head of Central Labs in the Americas with sites in North and South America and with over 500 employees.
“I am thrilled to be joining the NEOMED-LABS / Pacific Biomarkers leadership team. I had the opportunity to support Ampersand Capital during due diligence of both acquisitions and I was impressed with both companies. I am convinced the merger of these companies is the next big thing to happen in the speciality lab field. The depth of scientific expertise, the calibre of the people, and the experienced leadership team provide a solid foundation for future growth and expansion of the business,” said Tim McGrath, Chief Operating Officer of NEOMED-LABS / Pacific Biomarkers.
“NEOMED-LABS / Pacific Biomarkers was acquired by the management and Ampersand Capital last August in a first inorganic initiative which enabled the formation of a leading player in the immunology field with its 150 experts. We believe, based on our double claim of versatile expertise and state-of-the-art fully automated platforms, to have something unique to offer and expect to experience very solid growth in the years to come. Strengthening the management team with another experienced executive keeps enhancing our current leadership and business growth strategy.” said Benoit Bouche, President and Chief Executive Officer of NEOMED-LABS / Pacific Biomarkers.
This appointment follows the recruitment of Abigail Brus as VP Operations in Seattle and of Saadya Fatmi as VP Operations in Laval. Brus was previously from Q2 Solutions and Covance where she spent over a decade in different management positions. Fatmi was previously the Senior Director of Biotrials Operations and comes with 25 years of experience in the CRO industry. The addition of these executives brings valuable leadership and the operational expertise needed to support the rapid growth projection for NEOMED-LABS / Pacific Biomarkers.
The recently merged NEOMED-LABS / Pacific Biomarkers (NLPBI) has announced the acquisition of PAIRimmune, a...
Ampersand Capital Partners has announced that it has completed an acquisition of Pacific Biomarkers and...